Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Consumer Updates

Consumer Updates

                        Animal & Veterinary
          Children's Health
          Cosmetics
          Dietary Supplements
          Drugs
          Food
          Medical Devices
          Nutrition
          Radiation-Emitting Products
          Tobacco Products
          Vaccines, Blood & Biologics


                        Artículos para el consumidor en español Home
          For Consumers
          Consumer Updates
          Lupus Therapies Continue to EvolveConsumer Updates Lupus Therapies Continue to Evolve
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              African-American woman speaking to African-American female doctor at desk in doctor's officeEspañol

Lupus can be a difficult disease to diagnose and to treat. Scientists continue to work to understand the genetic basis of this disease and develop new and more targeted therapies to treat it.

Each year, as many as 16,000 people in the U.S. are diagnosed with lupus, an autoimmune disease that can be fatal. (An autoimmune disease is an illness that makes your body attack itself.)

Although people of all races and ethnicities can have the disease, African American women are three times more likely than white, non-Hispanic women to have lupus. African American women also tend to develop the disease at a younger age and have more serious and life-threatening complications than white, non-Hispanic women. Lupus is also more common in women of Hispanic, Asian, and Native American descent.

Lupus is a chronic disease, meaning that treatment may help control it but that the illness never goes away. Someone with lupus will have good phases and bad phases. People with lupus have a range of symptoms, which can include extreme tiredness, pain or swelling in the joints, and headaches.

The root cause of lupus is not fully known, and there are many types of the disease. The most common form, called systemic lupus erythematosus, may cause mouth sores, rashes, fatigue, joint pain and swelling. This form also affects the kidneys.

Who Is Affected by Lupus

About 200,000 people in the U.S. are living with systemic lupus. According to the U.S. Centers for Disease Control and Prevention, 10 times more women than men have lupus, and the disease often starts between ages 15 and 44.

What makes lupus so hard to diagnose? The symptoms of lupus are different from person to person. The signs of lupus can show up in various ways and are often mistaken for symptoms of other diseases. Also, people with lupus can have different problems with their immune systems.

There is still a great need for better treatments, and scientists may be close to developing more refined therapies to help control symptoms and foster remission. The U.S. Food and Drug Administration’s Office of Women’s Health has funded several studies related to lupus and other autoimmune diseases. The FDA’s Office of Minority Health and Health Equity also has funded a study on lupus.

Because lupus has a disproportionate impact on racial and ethnic minority communities, it is critical to advance research into therapeutic treatments and increase diversity in clinical research to help ensure that the medical products being developed work for the people they are intended to help.

Targeted Therapies for Treating Lupus

Lupus can damage many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels and brain. Treatment for lupus depends on the part of the body being affected by the disease and the severity of the symptoms.

Part of what makes lupus research such a challenge is that the precise problem with the immune system is so different among patients, which is also true for how the disease presents itself. New research is trying to zero in on what the best targets might be.

Older medicines, such as corticosteroids, tend to suppress the whole immune system, which can be an effective but an unnecessarily excessive measure with many undesirable side effects. As the understanding of the disease has evolved in recent years, so too has the development of medicines that target the specific molecule (or molecules) in the immune system that may be causing the problem.

The FDA approved Benlysta (belimumab) – the first targeted therapy for lupus – in 2011 to treat systemic lupus in adults. The FDA later approved Benlysta to treat children as young as 5 years old. In 2020, Benlysta became the first FDA approved targeted therapy to treat adults who have lupus with kidney involvement, one of the more severe forms of this disease. In 2021, the FDA approved Saphnelo (anifrolumab-fnia), a targeted therapy to treat adults with systemic lupus.

Advances in the understanding and treatment of lupus over the last several decades have resulted in people with the disease living longer and better lives. Still, many people with lupus need more treatment options.

                                                                                  Content current as of:
      01/24/2024
              
              
Regulated Product(s)
		 DrugsHealth Topic(s)
			  LupusConsumer Updates

          
                        Animal & Veterinary
          Children's Health
          Cosmetics
          Dietary Supplements
          Drugs
          Food
          Medical Devices
          Nutrition
          Radiation-Emitting Products
          Tobacco Products
          Vaccines, Blood & Biologics


                        Artículos para el consumidor en español
 Consumer Updates Email
                        Subscribe to receive Consumer Updates email notifications.
    Subscribe to Consumer Updates
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop